192 related articles for article (PubMed ID: 33486762)
21. Intensive chemotherapy without radiotherapy gives more than 85% event-free survival for non-Hodgkin lymphoma without central nervous involvement: a 6-year population-based study from the nordic society of pediatric hematology and oncology.
Márky I; Björk O; Forestier E; Jónsson OG; Perkkiö M; Schmiegelow K; Storm-Mathiesen I; Gustafsson G;
J Pediatr Hematol Oncol; 2004 Sep; 26(9):555-60. PubMed ID: 15342981
[TBL] [Abstract][Full Text] [Related]
22. Lymphocyte-predominant and classical Hodgkin's lymphoma: a comprehensive analysis from the German Hodgkin Study Group.
Nogová L; Reineke T; Brillant C; Sieniawski M; Rüdiger T; Josting A; Bredenfeld H; Skripnitchenko R; Müller RP; Müller-Hermelink HK; Diehl V; Engert A;
J Clin Oncol; 2008 Jan; 26(3):434-9. PubMed ID: 18086799
[TBL] [Abstract][Full Text] [Related]
23. Chemoresistant or aggressive lymphoma predicts for a poor outcome following reduced-intensity allogeneic progenitor cell transplantation: an analysis from the Lymphoma Working Party of the European Group for Blood and Bone Marrow Transplantation.
Robinson SP; Goldstone AH; Mackinnon S; Carella A; Russell N; de Elvira CR; Taghipour G; Schmitz N;
Blood; 2002 Dec; 100(13):4310-6. PubMed ID: 12393626
[TBL] [Abstract][Full Text] [Related]
24. Recurrence risk after organ transplantation in patients with a history of Hodgkin disease or non-Hodgkin lymphoma.
Trofe J; Buell JF; Woodle ES; Beebe TM; Hanaway MJ; First MR; Alloway RR; Gross TG
Transplantation; 2004 Oct; 78(7):972-7. PubMed ID: 15480161
[TBL] [Abstract][Full Text] [Related]
25. Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL--experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesis.
Scholz M; Engert A; Franklin J; Josting A; Diehl V; Hasenclever D; Loeffler M
Ann Oncol; 2011 Mar; 22(3):681-688. PubMed ID: 20720088
[TBL] [Abstract][Full Text] [Related]
26. Social inequality and incidence of and survival from Hodgkin lymphoma, non-Hodgkin lymphoma and leukaemia in a population-based study in Denmark, 1994-2003.
Roswall N; Olsen A; Christensen J; Rugbjerg K; Mellemkjaer L
Eur J Cancer; 2008 Sep; 44(14):2058-73. PubMed ID: 18657412
[TBL] [Abstract][Full Text] [Related]
27. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
28. The German Hodgkin Study Group risk model is useful for Hodgkin lymphoma patients receiving radiotherapy after autologous stem cell transplant.
Furlan C; Matrone F; Rupolo M; Ciancia R; Zanet E; Montante B; Palazzari E; Navarria F; Trovo M; Bulian P; Spina M; Coassin E; Mascarin M; De Paoli A; Franchin G; Michieli M
Cancer Radiother; 2019 Sep; 23(5):378-384. PubMed ID: 31178272
[TBL] [Abstract][Full Text] [Related]
29. Survival of patients with non-Hodgkin lymphoma in Germany in the early 21st century.
Pulte D; Jansen L; Gondos A; Emrich K; Holleczek B; Katalinic A; Brenner H;
Leuk Lymphoma; 2013 May; 54(5):979-85. PubMed ID: 23098058
[TBL] [Abstract][Full Text] [Related]
30. Carmustine, etoposide, cytarabine, and melphalan (BEAM)-campath allogeneic stem cell transplantation for aggressive non-hodgkin lymphoma: an analysis of outcomes from the British Society of Blood and Marrow Transplantation.
Truelove E; Fox C; Robinson S; Pearce R; Perry J; Kirkland K; McQuaker G; Pagliuca A; Johnson P; Russell N; Cook G;
Biol Blood Marrow Transplant; 2015 Mar; 21(3):483-8. PubMed ID: 25490180
[TBL] [Abstract][Full Text] [Related]
31. Lung cancer after treatment for non-Hodgkin lymphoma.
De Giacomo T; Martelli M; Venuta F; Anile M; Diso D; Di Stasio M; Rendina EA; Coloni GF
Minerva Chir; 2006 Dec; 61(6):467-71. PubMed ID: 17211351
[TBL] [Abstract][Full Text] [Related]
32. Positron emission tomography with [18F]2-fluoro-D-2-deoxyglucose (FDG-PET) predicts relapse of malignant lymphoma after high-dose therapy with stem cell transplantation.
Becherer A; Mitterbauer M; Jaeger U; Kalhs P; Greinix HT; Karanikas G; Pötzi C; Raderer M; Dudczak R; Kletter K
Leukemia; 2002 Feb; 16(2):260-7. PubMed ID: 11840293
[TBL] [Abstract][Full Text] [Related]
33. FACTORS ASSOCIATED WITH INCREASED RED BLOOD CELLS TRANSFUSION REQUIREMENTS IN PATIENTS WITH HODGKIN AND NON-HODGKIN LYMPHOMA.
Ali S; Ali M; Badar F; Basit A; Hameed A
J Ayub Med Coll Abbottabad; 2015; 27(1):70-3. PubMed ID: 26182741
[TBL] [Abstract][Full Text] [Related]
34. Fractionated total-body irradiation, etoposide, and cyclophosphamide plus autografting in Hodgkin's disease and non-Hodgkin's lymphoma.
Horning SJ; Negrin RS; Chao JC; Long GD; Hoppe RT; Blume KG
J Clin Oncol; 1994 Dec; 12(12):2552-8. PubMed ID: 7989928
[TBL] [Abstract][Full Text] [Related]
35. Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience.
Bekoz H; Ozbalak M; Karadurmus N; Paydas S; Turker A; Toptas T; Tuglular TF; Altuntas F; Cakar MK; Sonmez M; Gulbas Z; Demir N; Kaynar L; Yildirim R; Karadogan I; Arat M; Kapucu I; Aslan NA; Ozkocaman V; Turgut M; Yuksel MK; Ozcan M; Hacioglu SK; Barista I; Demirkaya M; Saydam G; Toprak SK; Yilmaz M; Demirkol O; Ferhanoglu B
Ann Hematol; 2020 Nov; 99(11):2565-2576. PubMed ID: 32507911
[TBL] [Abstract][Full Text] [Related]
36. Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.
Pinnix CC; Osborne EM; Chihara D; Lai P; Zhou S; Ramirez MM; Oki Y; Hagemeister FB; Rodriguez AM; Samaniego F; Fowler N; Romaguera JE; Turturro F; Fayad L; Westin JR; Nastoupil L; Neelapu SS; Cheah CY; Dabaja BS; Milgrom SA; Smith GL; Horace P; Milbourne A; Wogan CF; Ballas L; Fanale MA
JAMA Oncol; 2016 Aug; 2(8):1065-9. PubMed ID: 27227654
[TBL] [Abstract][Full Text] [Related]
37. Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century - a Swedish lymphoma register study.
Ekberg S; E Smedby K; Glimelius I; Nilsson-Ehle H; Goldkuhl C; Lewerin C; Jerkeman M; Eloranta S
Br J Haematol; 2020 Jun; 189(6):1083-1092. PubMed ID: 32065396
[TBL] [Abstract][Full Text] [Related]
38. Cause-specific mortality among Medicare beneficiaries with newly diagnosed non-Hodgkin lymphoma subtypes.
Hester LL; Park SI; Wood WA; Stürmer T; Brookhart MA; Lund JL
Cancer; 2019 Apr; 125(7):1101-1112. PubMed ID: 30548238
[TBL] [Abstract][Full Text] [Related]
39. Factors associated with survival in patients with progressive disease following autologous transplant for lymphoma.
Paltiel O; Rubinstein C; Or R; Nagler A; Gordon L; Deutsch L; Polliack A; Naparstek E
Bone Marrow Transplant; 2003 Apr; 31(7):565-9. PubMed ID: 12692622
[TBL] [Abstract][Full Text] [Related]
40. Characteristics and outcomes of patients with nodular lymphocyte-predominant Hodgkin lymphoma versus those with classical Hodgkin lymphoma: a population-based analysis.
Gerber NK; Atoria CL; Elkin EB; Yahalom J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):76-83. PubMed ID: 25863756
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
